Jeremy Livianu
Consigliere Generale presso UPHEALTH, INC.
Profilo
Jeremy Livianu is currently the Chief Legal Officer at UpHealth, Inc. He previously worked as the Director of Legal Affairs at Nevro Corp., Corporate Counsel at Tethys Bioscience, Inc., General Counsel at Establishment Labs Holdings, Inc., and Secretary, Vice President & General Counsel at Cutera, Inc. He received his undergraduate degree from the University of California San Diego and his doctorate from George Washington University Law School.
Posizioni attive di Jeremy Livianu
Società | Posizione | Inizio |
---|---|---|
UPHEALTH, INC. | Consigliere Generale | 01/03/2023 |
Precedenti posizioni note di Jeremy Livianu
Società | Posizione | Fine |
---|---|---|
CUTERA, INC. | Consigliere Generale | 01/12/2022 |
ESTABLISHMENT LABS HOLDINGS INC. | Consigliere Generale | 01/10/2020 |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Consigliere Generale | - |
NEVRO CORP. | Consigliere Generale | - |
Formazione di Jeremy Livianu
George Washington University Law School | Doctorate Degree |
University of California San Diego | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
ESTABLISHMENT LABS HOLDINGS INC. | Health Technology |
NEVRO CORP. | Health Technology |
CUTERA, INC. | Health Technology |
UPHEALTH, INC. | Health Services |
Aziende private | 1 |
---|---|
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Health Technology |
- Borsa valori
- Insiders
- Jeremy Livianu